About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring, enabling them to save and enhance lives. Additional company information can be found at www.edwards.com.
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
1. Hamilton M, Cecconi M, Rhodes A: A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve outcomes in moderate and high-risk surgery. Anesth Analg 2011; 112:1392-1402
2. Pearse RM, Harrison DA, McDonald N, Gillies MA, Blunt M, Ackland G, Grocott MPW, Ahern A, Griggs K, Scott R, Hinds C, Rowan K: Effect of a perioperative, cardiac output-guided, hemodynamic therapy algorithm on outcomes following major astrointestinal surgery: A randomized clinical trial and updated systematic review. JAMA 2014
3. Mythen MG, Swart M, Acheson N, Crawford R, Jones K, Kuper M, McGrath JS, Horgan A: Perioperative fluid management: Consensus statement from the enhanced recovery partnership. Perioperative Medicine 2012; 1:2
4. Vallet B, Blanloeil Y, Cholley B, Orliaguet G, Pierre S, Tavernier B. Guidelines for perioperative haemodynamic optimization. Ann Fr Anesth Reanim 2013; 32:454-62
5. Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, McNaught CE, MacFie J, Liberman AS, Soop M, Hill A, Kennedy RH, Lobo DN, Fearon K, Ljungqvist O: Guidelines for perioperative care in elective colonic surgery: enhanced recovery after surgery (ERAS) society. World J Surg 2013; 37:259-284
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to Dr. Manecke's statements and statements regarding potential cost savings and benefits of PGDT. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.
Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors including but not limited to broader clinical experience and economic analysis of PGDT, or unexpected changes or delays related to supply, quality and availability of products used in PGDT, or regulatory decisions. These factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2013.
